Recruiting

Nevisense Go

Sponsor:

Castle Biosciences Incorporated

Code:

NCT07645820

Conditions

Atopic Dermatitis

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

Nevisense electrical impedance spectroscopy

Study Details

Brief summary:

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.

Conditions

Atopic Dermatitis

Study ID

NCT07645820

Start date

May 29, 2026

Status verified date

Jun, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Apr 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Participants may be eligible if they:

  • Are 12 to 89 years old.
  • Have been diagnosed with atopic dermatitis (eczema).
  • Have had at least one atopic dermatitis flare within the past 2 months.
  • Are willing and able to use the Nevisense Go device at home, complete an electronic symptom diary, and attend study visits.
  • If currently using systemic treatment for atopic dermatitis, have been on the same treatment for at least 3 months and do not plan to change treatment during the study.

Exclusion Criteria:

Participants may not be eligible if they:

  • Are unwilling or unable to avoid applying creams, lotions, ointments, or soap to measurement areas for 6 hours before measurements.
  • Do not have suitable skin areas for study measurements.
  • Have another skin condition that may affect study assessments.
  • Are pregnant.

Study Design

Enrollment

450 participants

Anticipated

Interventions and Outcome Measures

Interventions

Nevisense electrical impedance spectroscopy

The NevisenseGo device will collect skin measurements from people with atopic dermatitis (AD) to see if it can effectively predict a flare in disease.

Primary outcome measure

  • Relationship between skin measurements and subsequent atopic dermatitis flares [ Time Frame: Measurements taken over 90 days, 5 days a week ]
  • Develop and validate an algorithm using Nevisense Go EIS [ Time Frame: From enrollment until end of treatment at 90 days. ]

Central Contacts and Locations

Central contacts

Clare Johnson E VP Clinical Research

602-499-0301cjohnson@castlebiosciences.com

Locations

U.S. Dermatology Partners

Recruiting

Phoenix, Arizona, United States, 85006

Principal Investigator:

Margaret Kessler, MD

Las Vegas Dermatology

Recruiting

Las Vegas, Nevada, United States, 89144

Principal Investigator:

David Cotter, MD, PhD

StracSkin, PLLC

Recruiting

Portsmouth, New Hampshire, United States, 03801

Principal Investigator:

Abel Jarell, MD, FAAD

Harrison Institute for Clinical Research

Recruiting

Missouri City, Texas, United States, 77459

More Information

Sponsor

Castle Biosciences Incorporated

Last update posted

Jun 12, 2026

Last verified

Jun, 2026

Keywords

  • Electrical Impedance Spectroscopy
  • EIS
  • Atopic Dermatitis
  • Eczema
  • Flare
  • Skin barrier function
  • Flare Prediction
  • Dermatology
  • Nevisense Go
  • Skin Barrier Dysfunction

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Castle Biosciences Incorporated on 2026-06-12.